As a critical administrative hearing on federal cannabis reform kicks off this week, the political winds in Washington appear to be blowing in favor of change. Despite a recent attempt by the House Appropriations Committee to include language that would defund and block the Trump administration’s rescheduling efforts, bipartisan lawmakers are signaling that these efforts are unlikely to gain any real traction.
The proposed “rider”—which would strip federal funding for any agency efforts to reschedule or deschedule marijuana—has been a recurring feature in appropriations bills for years. Yet, it has never successfully crossed the finish line to become law, and many in Congress don’t see that changing now.
Rep. Byron Donalds (R-FL) captured the sentiment of many colleagues, noting that even among those skeptical of full legalization, there is little appetite to pick this specific fight. “I don’t see how they’re going to get it through,” Donalds told Marijuana Moment. “There’s a bunch of other things that we need to worry on and get focused on.”
The conversation around cannabis on Capitol Hill is evolving. While some lawmakers remain firm in their personal opposition to recreational use, even the most traditional critics are showing increased flexibility regarding medical applications.
Rep. Chuck Fleischmann (R-TN), who describes himself as someone who has never touched alcohol or marijuana, expressed a newfound openness to the medical benefits of the plant. After speaking with constituents suffering from chronic pain and chemotherapy side effects, Fleischmann admitted he is “not on the winning side of that issue long term,” signaling a broader realization among veteran legislators that public opinion has shifted significantly.
On the other side of the aisle, proponents like Rep. Lou Correa (D-CA) are doubling down on the futility of the “War on Drugs” approach. Pointing to the widespread acceptance of cannabis across the vast majority of U.S. states, Correa noted, “What do you want to do, arrest everybody? Is that the solution? What about civil liberties here?”
This week’s hearing is a massive step in the formal administrative process. With the DEA actively involved and presenting medical evidence—including testimony on the benefits of cannabis for pain management—the proceedings are shedding light on the science that the administration is using to justify its rescheduling proposal.
While the medical side of the industry has already seen the benefits of the move to Schedule III that took effect earlier this year, the current hearing is aimed at broader, more permanent regulatory clarity. Even if a few vocal opponents attempt to block progress via budget riders, the current consensus on the Hill is that the movement is too large, too popular, and too far along to be derailed by procedural maneuvers.
For now, the wheels of government are turning—and it looks like they are moving forward, not backward.
Dabbin-Dad Newsroom
